W
Weixiao Han
Researcher at Sinovac Biotech
Publications - 8
Citations - 1135
Weixiao Han is an academic researcher from Sinovac Biotech. The author has contributed to research in topics: Immunogenicity & Vaccination. The author has an hindex of 4, co-authored 6 publications receiving 531 citations.
Papers
More filters
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Biao Kan,Yaling Hu,Haiyan Mao,Qian-Qian Xin,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Xuejie Gong,Chuan Qin,Yuansheng Hu,Xiao-Yong Liu,Guo-Liang Cui,Cong-Bing Jiang,Hengming Zhang,Jingxin Li,Minnan Yang,Xiao-Juan Lian,Yan Song,Jinxing Lu,Xiangxi Wang,Miao Xu,Qiang Gao,Fengcai Zhu +29 more
TL;DR: Favorable safety and immunogenicity of CoronaVac was demonstrated on both schedules and both dosages, which support the conduction of phase 3 trial with optimum schedule/dosage per different scenarios.
Journal ArticleDOI
Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.
TL;DR: The inactivated EV71 vaccine-induced immunity had a good persistence, within 5 years following the primary vaccination, and the SR and GMT in vaccine subjects remained significantly higher than that in the placebo subjects at all the sampling points.
Journal ArticleDOI
Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China.
Yuemei Hu,Kangwei Xu,Weixiao Han,Kai Chu,Deyu Jiang,Jianfeng Wang,Xiaohui Tian,Zhifang Ying,Ying Zhang,Changgui Li,Fengcai Zhu +10 more
TL;DR: The new sIPV demonstrated an immunogenicity noninferior to that of the wIPV and a good safety profile in sequential vaccination with bOPV.
Journal ArticleDOI
A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly
Lili Huang,Ling Wang,Hong Li,Yuansheng Hu,Wei-ping Ru,Weixiao Han,Gang Shi,Qiang Ye,Zhen Han,Jielai Xia,Shengli Xia,Miao Xu,Jing Li +12 more
TL;DR: The newly PPV23 is immunologically non-inferior to the control commercial vaccine and well tolerated in healthy Chinese population aged ≥ 2 years.